Cancer and its treatments, including chemotherapy, hormone therapy, and radiation therapy, can deleteriously affect a wide range of mental processes. [1] [2] [3] [4] Impairments in the main domains of attention, working memory, and other aspects of cognitive function constitute significant cancer-related adverse effects and are reported by 17-75% of patients. 2, [5] [6] [7] [8] [9] [10] [11] Previous studies have reported a higher incidence of cognitive dysfunction among cancer patients than in matched healthy controls. 2, 7 The degree of cancer-related cognitive dysfunction (CRCD) has been correlated with treatment dose. 9 CRCD can be debilitating and enduring. 1, 10, 12 A prospective longitudinal study of the effects of standard-dose adjuvant chemotherapy on cognitive functioning in women with breast cancer showed that 33 and 61% of patients reported cognitive impairment at baseline and after three weeks of chemotherapy, respectively. At one year post-chemotherapy, only 50% of patients who experienced cognitive declines showed improvement, whereas the other 50% simply demonstrated stabilization in cognitive function without improvement.
daily psychosocial functioning. Many factors, including personal characteristics of patients, tumor biology, treatment regimen, and environmental supports, may affect the severity of CRCD.
Assessment of Cancer-related Cognitive Dysfunction
Reliable screening and assessment of CRCD are the sine qua non for the development of reliable and effective interventions to control this symptom for cancer patients and survivors. However, no 'gold standard' measures have been developed and specifically validated for screening and/or assessment of CRCD. No consensus exists in terms of the best methods for assessing this symptom. The trend in the medical literature is to utilize objective neuropsychological measures and compare the performance of cancer patients with a reference or healthy control group in order to determine cognitive dysfunction. Consequently, studies on the effects of cancer and its treatments on cognitive functioning have used a variety of established neuropsychological tests.
It has been recommended that basic neuropsychological tests for assessing CRCD should include measures of attention, learning, memory, processing speed, and psychological distress such as depression and anxiety. 23 Finally, the adjustment element on the continuum involves regular re-examination of symptoms, interventions, and behavioral performance to fully understand the relevance and effectiveness of the intervention and fine-tuning the intervention to achieve an optimal outcome.
Non-pharmacological or Behavioral Interventions
Recent preliminary studies have supported the possible beneficial effect of behavioral interventions to control CRCD. 33, 38 Behavioral interventions could help cancer patients and survivors find ways to control their problems in attention, memory, and other aspects of cognitive function.
This type of intervention includes compensatory approaches that could involve establishing structures in daily routine, using assisted technologies and reminders to aid memory, training in attention and ways to avoid distraction, physical activity, cognitive behavioral therapy, improvement in nutrition and sleep, and participation in mental exercises and brain-plasticity-based cognitive training. 39 
Pharmacological Interventions
Two recent preliminary studies from our research group at the University survivors. 41 Another pilot study from our group at the URMC examined the neuroprotective effect of paroxetine hydrochloride (Paxil) on chemotherapy-induced problems in attention and memory. 40 The sample included 781 cancer patients (574 females and 207 males) between 22 and 87 years of age. Memory was assessed using a brief patient self-reported memory problem (SRMP) measure consisting of items from the fatigue symptom checklist that relate to memory dysfunction. Psychometric analyses showed that the SRMP was a reliable brief screening that accounted for 72% of the variance in reported memory problems. Our analysis showed a statistically significant effect of Paxil (p<0.05). CRCD is a serious problem for cancer patients and survivors that could be alleviated by Paxil. Further studies are needed to replicate these findings and also to examine the usefulness of other psychotropic agents and combined behavioral and pharmacological interventions to control CRCD.
Combined BehavioralPsychopharmacological Interventions
Preliminary data suggest potential beneficial effects of both pharmacological and non-pharmacological or behavioral interventions control CRCD for patients and survivors. It is possible that pharmacotherapy could enhance the effects of behavioral interventions or vice versa. Further studies are needed to examine the relationship between pharmacological and non-pharmacological interventions.
Conclusion
The incidence and prevalence of cancer are rapidly rising, making this disease a major worldwide public health problem. 42, 43 While advances in medical research and cancer therapies have resulted in increased survival, cancer patients and survivors face major challenges associated with
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